Pemvidutide belongs to the branch of the obesity-drug family that does more than quiet appetite — it also tries to rev up metabolism and clean out the liver. It does that by adding a second, older hormone to the GLP-1 formula: glucagon. It is still investigational, but its early liver data is striking.
In plain terms: it's a GLP-1 weight-loss drug with a "burn" lever bolted on — and that lever happens to be very good at stripping fat from the liver.
What it is
Pemvidutide is a GLP-1/glucagon receptor dual agonist developed by Altimmune, given by weekly subcutaneous injection1. One molecule, two levers:
- GLP-1 receptor — curbs appetite, the familiar weight-loss mechanism.
- Glucagon receptor — the added lever, which raises energy expenditure and mobilizes fat, particularly in the liver.
That puts it in the same glucagon-containing family as retatrutide (a triple agonist) and survodutide (also GLP-1/glucagon) — drugs designed to do more than a pure GLP-1 can4.
The glucagon angle
Glucagon has an interesting reputation. For decades it was seen as a *problem* hormone in metabolic disease — it raises blood sugar — which is why a recent review literally frames the shift as "from foe to friend": repurposing glucagon to treat obesity and diabetes3. The rehabilitation works because, paired with GLP-1, glucagon's useful effects come forward: it increases energy expenditure (how many calories the body burns) and drives fat out of the liver, while the GLP-1 arm offsets its tendency to nudge glucose upward3.
That dual action is why glucagon-based multi-agonists — mazdutide, pemvidutide, survodutide, retatrutide — have produced significant weight loss in trials, often surpassing existing therapies, along with benefits for obesity-related conditions2. Pemvidutide's particular calling card is the liver.
What the trials actually found
Pemvidutide's standout evidence so far is in fatty-liver disease:
| Study | Design | Key result | Year |
|---|---|---|---|
| Browne et al. — MASLD1 | 24-week randomized, placebo-controlled (1.2 / 1.8 / 2.4 mg weekly) | Liver-fat content fell ~56%, 75%, and 76% by dose after 24 weeks | 2025 |
In the MASLD trial, participants (average BMI ~37, average liver-fat content ~22%) received weekly pemvidutide for 24 weeks1. Liver fat — measured directly by MRI — dropped by roughly 56% at the lowest dose and about 76% at the highest1. Reductions of that size are exactly what the field is chasing in metabolic dysfunction-associated steatohepatitis (MASH), the more serious form of fatty-liver disease. Alongside the liver work, pemvidutide is also being developed for general obesity, where the glucagon-combo class has produced substantial weight loss2.
In plain terms: in people with fatty liver, it removed a large fraction of the liver's fat in about six months.
Side effects and safety
The safety story mixes the familiar with the glucagon-specific. Like the whole class, its most common side effects are gastrointestinal — nausea, vomiting, diarrhea — usually dose-dependent and worst during dose escalation. The glucagon arm adds its own watch-items: because glucagon can raise blood sugar and heart rate, those are monitored in trials, with the GLP-1 arm working to counter the glucose effect3. The honest caveats:
- It's phase-2-stage. The liver trial was modest in size and 24 weeks long1; rare and long-term risks aren't characterized yet.
- Glucagon biology cuts both ways. The "foe to friend" reframing is promising but still being validated in large trials3 — the long-term metabolic balance is what those trials must confirm.
Investigational status
To be plain: pemvidutide is not an approved medicine. As of 2026 it is an Altimmune candidate with phase-2 data in both fatty-liver disease and obesity, and larger trials ahead. Everything solid known about it comes from those studies. This page explains what it is and what the trials showed — not how to use it — and it takes no position on sourcing.
The short version
Pemvidutide is a GLP-1/glucagon dual agonist — appetite suppression plus a glucagon "burn-and-clear" lever that raises energy expenditure and strips fat from the liver3. In a MASLD trial it cut liver fat by roughly 56–76% over 24 weeks1, and its glucagon-combo class has driven significant weight loss in obesity trials2. It is investigational, phase-2-stage, and unapproved — an educational overview only, not medical advice.